181 related articles for article (PubMed ID: 24142545)
1. Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.
Yao Y; Wang H; Li B; Tang Y
Tumour Biol; 2014 Mar; 35(3):2157-66. PubMed ID: 24142545
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
3. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.
Pettersson A; Lis RT; Meisner A; Flavin R; Stack EC; Fiorentino M; Finn S; Graff RE; Penney KL; Rider JR; Nuttall EJ; Martin NE; Sesso HD; Pollak M; Stampfer MJ; Kantoff PW; Giovannucci EL; Loda M; Mucci LA
J Natl Cancer Inst; 2013 Dec; 105(24):1881-90. PubMed ID: 24292212
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
5. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
6. Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer.
Motamedinia P; Scott AN; Bate KL; Sadeghi N; Salazar G; Shapiro E; Ahn J; Lipsky M; Lin J; Hruby GW; Badani KK; Petrylak DP; Benson MC; Donovan MJ; Comper WD; McKiernan JM; Russo LM
PLoS One; 2016; 11(5):e0154507. PubMed ID: 27144529
[TBL] [Abstract][Full Text] [Related]
7. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.
Lu B; Maqsodi B; Yang W; McMaster GK; Perner S; Regan M; Bubley GJ; Balk SP; Rubin M; Sanda MG
Urology; 2009 Nov; 74(5):1156-61. PubMed ID: 19647299
[TBL] [Abstract][Full Text] [Related]
8. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
9. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.
Huang L; Schauer IG; Zhang J; Mercado-Uribe I; Deavers MT; Huang J; Liu J
Int J Clin Exp Pathol; 2011; 4(7):644-50. PubMed ID: 22076164
[TBL] [Abstract][Full Text] [Related]
11. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
12. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
[TBL] [Abstract][Full Text] [Related]
13. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
Clark JP; Munson KW; Gu JW; Lamparska-Kupsik K; Chan KG; Yoshida JS; Kawachi MH; Crocitto LE; Wilson TG; Feng Z; Smith SS
Clin Chem; 2008 Dec; 54(12):2007-17. PubMed ID: 18948370
[TBL] [Abstract][Full Text] [Related]
14. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.
Nam RK; Sugar L; Yang W; Srivastava S; Klotz LH; Yang LY; Stanimirovic A; Encioiu E; Neill M; Loblaw DA; Trachtenberg J; Narod SA; Seth A
Br J Cancer; 2007 Dec; 97(12):1690-5. PubMed ID: 17971772
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
Brase JC; Johannes M; Mannsperger H; Fälth M; Metzger J; Kacprzyk LA; Andrasiuk T; Gade S; Meister M; Sirma H; Sauter G; Simon R; Schlomm T; Beissbarth T; Korf U; Kuner R; Sültmann H
BMC Cancer; 2011 Dec; 11():507. PubMed ID: 22142399
[TBL] [Abstract][Full Text] [Related]
17. Predictive significance of
Song C; Chen H
Cancer Cell Int; 2018; 18():177. PubMed ID: 30459527
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
